clinical trial · NCT02802423
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
BioLite, Inc.·phase2·not yet recruiting·n = 44
Triple Negative Breast CancerBLEX 404 Oral Liquid
brief summary
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.
started
Jan 1, 2027
primary completion
Apr 30, 2028
completion
Aug 28, 2028
last updated
Apr 13, 2026
official title
A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol